Aurora Biopharma - Innovative Cancer Immunotherapy Technolgoy
The human body has a powerful immune system, and one of its white blood cells called a T-cell is like a solider capable of attacking and killing abnormal cancerous cells. However, in cancer patients, these T cells are compromised, either fail to target or recognize cancerous cells, or are too few in number to lead an strong attack. Aurora’s revolutionary CAR T Cell Therapy change a cancer patient’s own weak T cells into “bionic” killing machines —a highly targeted army that can kill cancer. A cancer patient’s T cells are removed from a blood draw, genetically engineered in a laboratory, expanded to almost a billion CAR T cells, and re-infused back into the patient where they are better able to kill cancer.
-
Most popular related searches
Platform
Human Epidermal Growth Factor Receptor 2 (HER2) has been shown to be expressed in numerous cancers. Overexpressed, or gene amplified HER2 is an established solid tumor target involved in regulating tumor cell growth.
Glioblastoma
GBM Treatment Market expected to rise 5x to $3.3 billion by 2024, across the major markets of the US, Europe, and Japan, primarily due to the launch of new therapies (Global Data)
Aurora is researching Bispecfic CAR T Cell Therapy targeting HER2 and GD2 against Glioblastoma.
Customer reviews
No reviews were found for Aurora Biopharma - Innovative Cancer Immunotherapy Technolgoy. Be the first to review!